COVID-19 and β-thalassemia: in lieu of evidence and vague nexus.
Hayder M Al-KuraishyMohamed H Mazhar AshourHebatallah M SaadGaber El-Saber BatihaPublished in: Annals of hematology (2023)
Coronavirus disease 19 (COVID-19) is an infectious disease caused by severe acute respiratory coronavirus 2 (SARS-CoV-2) causing acute systemic disorders and multi-organ damage. β-thalassemia (β-T) is an autosomal recessive disorder leading to the development of anemia. β-T may lead to complications such as immunological disorders, iron overload, oxidative stress, and endocrinopathy. β-T and associated complications may increase the risk of SARS-CoV-2, as inflammatory disturbances and oxidative stress disorders are linked with COVID-19. Therefore, the objective of the present review was to elucidate the potential link between β-T and COVID-19 regarding the underlying comorbidities. The present review showed that most of the β-T patients with COVID-19 revealed mild to moderate clinical features, and β-T may not be linked with Covid-19 severity. Though patients with transfusion-dependent β-T (TDT) develop less COVID-19 severity compared to non-transfusion-depend β-T(NTDT), preclinical and clinical studies are recommended in this regard.
Keyphrases
- sars cov
- coronavirus disease
- respiratory syndrome coronavirus
- oxidative stress
- cardiac surgery
- risk factors
- sickle cell disease
- dna damage
- liver failure
- chronic kidney disease
- mesenchymal stem cells
- intensive care unit
- acute respiratory distress syndrome
- single cell
- acute kidney injury
- bone marrow
- hepatitis b virus
- diabetic rats
- autism spectrum disorder
- ischemia reperfusion injury
- endoplasmic reticulum stress
- cell therapy
- heat shock protein